Comparing two drug combinations for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer called HR-positive and HER2-negative that has spread or cannot be removed with surgery.
- Your cancer has a specific change in the PIK3CA gene, which must be confirmed by a test.
- You have tried at least one or two hormone therapies, and the cancer has continued to grow.
- You have taken only one type of CDK4/6 inhibitor (a class of targeted therapy) in the past, either with hormone therapy for advanced disease or as an adjuvant treatment.
- You are generally well enough to carry out daily activities (ECOG score of 0 or 1).
- You have not had previous treatment with certain drug classes, including PI3K inhibitors, AKT inhibitors, mTOR inhibitors, immunotherapy, or antibody-drug conjugates.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests a new drug, inavolisib, combined with two standard treatments (fulvestrant and palbociclib) for people with advanced breast cancer and type 2 diabetes. It aims to find out if this combination is safe and effective.
This study tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) for women with advanced breast cancer that is hormone-receptor positive and HER2-negative, with a specific genetic mutation (PIK3CA). The goal is to see if this combination can shrink or control the cancer better than standard treatments.
Hear when a new PIK3CA Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.